AI Article Synopsis
Article Abstract
Background: Patients with inflammatory bowel disease (IBD) often report symptoms compatible with irritable bowel syndrome (IBS), which might have an effect on psychological health. However, previous estimates of the magnitude of this issue have not accounted for ongoing inflammation as the potential cause. We updated a previous systematic review and meta-analysis to determine prevalence of IBS-type symptoms in patients with IBD in remission to better quantify the magnitude of this issue.
Methods: In this systematic review and meta-analysis, Embase, Embase Classic, and MEDLINE were searched (from Jan 1, 2012, to May 11, 2020) to identify prospective case-control or cross-sectional studies reporting prevalence of symptoms meeting diagnostic criteria for IBS in adults with IBD in remission. Studies were required to have recruited an unselected adult population (more than 90% of participants aged ≥16 years) with histologically or radiologically confirmed IBD and include at least 50 participants. Pooled prevalence and odds ratios (ORs) with 95% CIs were calculated according to the definition of remission, criteria used to define IBS-type symptoms, and type of IBD. The association between IBS-type symptom reporting and psychological comorbidity was examined using weighted mean difference (WMD) or standardised mean difference (SMD) in anxiety and depression scores between those reporting IBS-type symptoms and those not, for cases in which these data were available.
Findings: Of 3370 studies identified, 27 were eligible, of which 18 were newly identified. Among 3169 patients with IBD in remission, pooled prevalence of IBS-type symptoms was 32·5% (95% CI 27·4-37·9; I=90·1%). Prevalence was lower when remission was defined by endoscopic assessment (23·5%, 95% CI 17·9-29·6; I=59·9%) or histological assessment (25.8%, 95% CI 20.2-31.7; I=not applicable) than when defined by validated clinical disease activity index (33·6%, 26·3-41·2; I=91·8%) and higher in Crohn's disease than in ulcerative colitis (36·6%, 29·5-44·0; I=82·9% vs 28·7%, 22·9-34·8; I=87·2%). Anxiety (WMD 2·5; 95% CI 0·8-4·3) and depression (SMD 0·64; 0·44-0·84) scores were significantly higher among those who reported IBS-type symptoms than in those who did not.
Interpretation: Prevalence of symptoms compatible with IBS in patients with IBD varied according to how remission was defined. However, even when stringent criteria such as endoscopic or histological remission were used, about a quarter of patients reported these symptoms. Such symptoms were more common in patients with Crohn's disease and were associated with psychological comorbidity. Addressing psychological wellbeing might improve outcomes in this specific group of patients.
Funding: None.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2468-1253(20)30300-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Inflammatory bowel disease (IBD) causes fatigue, pain and faecal urgency/incontinence symptoms. Identifying symptom profile subgroups and related psychological correlates might enable earlier intervention and more effective tailored treatment pathways.
Methods: This study was nested within a randomised controlled trial of a digital symptom intervention for people with IBD (n=780).
The prevalence of small intestine bacterial overgrowth in irritable bowel syndrome is much higher with lactulose than glucose breath test: Results of a retrospective monocentric study.
Clin Res Hepatol Gastroenterol
November 2024
Hospices Civils de Lyon, Service de Biochimie et Biologie Moléculaire, Pierre Bénite, France.
Article Synopsis
- The study aimed to determine if lactulose breath tests (LBT) are more effective than glucose breath tests (GBT) for diagnosing small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) patients.
- Among 287 IBS patients analyzed, LBT showed a significantly higher prevalence of SIBO at 47% compared to just 4.5% for GBT, indicating that the tests are not interchangeable.
- Despite the different SIBO prevalence rates, neither test showed a correlation with the severity of IBS symptoms, suggesting limited clinical usefulness for diagnosing SIBO in these patients.
Review article: The role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications.
Aliment Pharmacol Ther
November 2024
Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Background: Treatments targeting the gut-brain axis (GBA) are effective at reducing symptom burden in irritable bowel syndrome (IBS). The prevalence of common mental disorders and IBS-type symptom reporting is significantly higher in inflammatory bowel disease (IBD) than would be expected, suggesting potential GBA effects in this setting. Manipulation of the GBA may offer novel treatment strategies in selected patients with IBD.
View Article and Find Full Text PDFMast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management.
Curr Gastroenterol Rep
April 2024
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Purpose Of Review: Mast cell activation syndrome (MCAS) is a clinical disorder that may explain irritable bowel syndrome (IBS) type symptoms as well as other allergic symptoms experienced by an individual. The diagnosis and treatment of MCAS with specific focus on gastrointestinal (GI) manifestations is reviewed.
Recent Findings: Although biomarkers for MCAS remain elusive, testing for baseline serum tryptase will distinguish the type of mast cell disorder and urine tests for mast cell mediator metabolites may support the diagnosis.
PMA - Zeolite (Clinoptilolite) in the Management of Irritable Bowel Syndrome - a Non-Interventional Study.
Z Gastroenterol
March 2024
KIM III/Gastroenterol., MedUniWien, Vienna, Austria.
Unlabelled: In clinical practice, the treatment of patients with irritable bowel syndrome (IBS) can be very challenging. The aims of the present non-interventional study (NIS) were to investigate the tolerability and efficacy of PMA-zeolite under everyday conditions in patients with diarrheic IBS type (IBS-D) or constipated type (IBS-C) or mixed type (IBS-M).
Methods: To document prospective data on tolerability and symptom frequency in the frame of a nationwide NIS, we recruited 204 IBS patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!